Axsome Therapeutics (AXSM) Expected to Announce Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) is expected to post its Q3 2025 results before the market opens on Monday, November 3rd. Analysts expect Axsome Therapeutics to post earnings of ($0.80) per share and revenue of $162.9560 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2025 earningreport page for the latest details on the call scheduled for Monday, November 3, 2025 at 8:00 AM ET.

Axsome Therapeutics (NASDAQ:AXSM) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.08. Axsome Therapeutics had a negative net margin of 49.88% and a negative return on equity of 283.22%. The firm had revenue of $150.04 million for the quarter, compared to the consensus estimate of $140.02 million. On average, analysts expect Axsome Therapeutics to post $-3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Axsome Therapeutics Stock Up 1.4%

Shares of Axsome Therapeutics stock opened at $134.99 on Friday. The firm’s 50 day moving average price is $123.08 and its 200-day moving average price is $112.47. The company has a quick ratio of 1.51, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. Axsome Therapeutics has a 52-week low of $75.56 and a 52-week high of $139.13. The company has a market cap of $6.74 billion, a P/E ratio of -26.63 and a beta of 0.52.

Analyst Ratings Changes

AXSM has been the topic of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday, October 8th. Morgan Stanley upped their price objective on shares of Axsome Therapeutics from $191.00 to $194.00 and gave the company an “overweight” rating in a report on Monday, October 20th. Royal Bank Of Canada upped their price objective on shares of Axsome Therapeutics from $184.00 to $189.00 and gave the company an “outperform” rating in a report on Tuesday, August 5th. Needham & Company LLC reaffirmed a “buy” rating and issued a $150.00 price objective on shares of Axsome Therapeutics in a report on Monday, August 4th. Finally, Bank of America upped their price objective on shares of Axsome Therapeutics from $173.00 to $176.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Axsome Therapeutics currently has a consensus rating of “Buy” and an average target price of $178.20.

Insider Activity at Axsome Therapeutics

In related news, CEO Herriot Tabuteau sold 27,907 shares of the business’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $118.96, for a total value of $3,319,816.72. Following the completion of the transaction, the chief executive officer directly owned 7,229 shares in the company, valued at $859,961.84. The trade was a 79.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Roger Jeffs sold 20,000 shares of the business’s stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $121.60, for a total transaction of $2,432,000.00. Following the completion of the transaction, the director owned 90,974 shares of the company’s stock, valued at approximately $11,062,438.40. This represents a 18.02% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 243,332 shares of company stock worth $28,824,746 in the last three months. Company insiders own 22.30% of the company’s stock.

Hedge Funds Weigh In On Axsome Therapeutics

A number of large investors have recently added to or reduced their stakes in AXSM. Adage Capital Partners GP L.L.C. raised its position in Axsome Therapeutics by 831.3% during the second quarter. Adage Capital Partners GP L.L.C. now owns 447,000 shares of the company’s stock worth $46,662,000 after acquiring an additional 399,000 shares during the period. Bank of America Corp DE raised its position in Axsome Therapeutics by 41.1% during the second quarter. Bank of America Corp DE now owns 753,429 shares of the company’s stock worth $78,650,000 after acquiring an additional 219,527 shares during the period. The Manufacturers Life Insurance Company raised its position in Axsome Therapeutics by 485.6% during the second quarter. The Manufacturers Life Insurance Company now owns 133,823 shares of the company’s stock worth $13,970,000 after acquiring an additional 110,972 shares during the period. Qube Research & Technologies Ltd raised its position in shares of Axsome Therapeutics by 38.7% in the second quarter. Qube Research & Technologies Ltd now owns 391,617 shares of the company’s stock valued at $40,881,000 after buying an additional 109,241 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of Axsome Therapeutics by 38.7% in the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock valued at $35,189,000 after buying an additional 84,151 shares during the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.